Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STA363 in lumbar disc herniation with radiculopathy
NCT06022263Phase 1Completed
- Sponsor
- Stayble Therapeutics
- Start
- Jul 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in lumbar disc herniation (LDH), radiculopathy and Sciatica comparing Placebo with STA363 (2 arms). Primary endpoint: Safety and Tolerability at 6 months. Started Jul 2023; status: completed.
02
Drugs
lactic acid
03
Conditions
lumbar disc herniation (LDH)radiculopathySciatica
Beyond the preview
Go deeper on NCT06022263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06022263.